Humana (NYSE:HUM)‘s stock had its “buy” rating restated by equities researchers at Cowen in a report released on Wednesday. They presently have a $285.00 price target on the insurance provider’s stock. Cowen’s target price indicates a potential upside of 11.92% from the company’s previous close.

HUM has been the subject of several other research reports. Credit Suisse Group dropped their price objective on Humana from $256.00 to $246.00 and set a “neutral” rating for the company in a research note on Friday, November 10th. ValuEngine lowered Humana from a “buy” rating to a “hold” rating in a research note on Tuesday, October 10th. BidaskClub raised Humana from a “sell” rating to a “hold” rating in a research note on Wednesday, August 23rd. Jefferies Group reissued a “hold” rating and set a $257.00 price objective on shares of Humana in a research note on Friday, October 13th. Finally, BMO Capital Markets lifted their price objective on Humana from $290.00 to $300.00 and gave the company an “outperform” rating in a research note on Friday, November 10th. Twelve equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus price target of $256.30.

Humana (NYSE:HUM) traded up $1.61 during trading hours on Wednesday, reaching $254.64. The company had a trading volume of 898,800 shares, compared to its average volume of 1,377,120. The company has a market capitalization of $36,147.89, a price-to-earnings ratio of 21.59, a price-to-earnings-growth ratio of 1.74 and a beta of 0.88. Humana has a 12 month low of $186.25 and a 12 month high of $264.56. The company has a quick ratio of 1.61, a current ratio of 1.61 and a debt-to-equity ratio of 0.35.

Humana (NYSE:HUM) last posted its quarterly earnings data on Wednesday, November 8th. The insurance provider reported $3.39 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $3.27 by $0.12. The company had revenue of $13.28 billion during the quarter, compared to analyst estimates of $13.41 billion. Humana had a return on equity of 15.99% and a net margin of 3.49%. The firm’s quarterly revenue was down 3.0% on a year-over-year basis. During the same quarter last year, the company earned $3.18 earnings per share. equities analysts predict that Humana will post 11.63 earnings per share for the current year.

A number of hedge funds have recently modified their holdings of the business. AXA increased its holdings in shares of Humana by 24.2% in the third quarter. AXA now owns 34,900 shares of the insurance provider’s stock worth $8,503,000 after buying an additional 6,800 shares during the period. Public Employees Retirement System of Ohio increased its holdings in shares of Humana by 2.4% in the third quarter. Public Employees Retirement System of Ohio now owns 98,701 shares of the insurance provider’s stock worth $24,047,000 after buying an additional 2,348 shares during the period. GSA Capital Partners LLP increased its holdings in shares of Humana by 159.3% in the third quarter. GSA Capital Partners LLP now owns 10,111 shares of the insurance provider’s stock worth $2,463,000 after buying an additional 6,211 shares during the period. Archford Capital Strategies LLC increased its holdings in shares of Humana by 22,823.5% in the third quarter. Archford Capital Strategies LLC now owns 3,897 shares of the insurance provider’s stock worth $949,000 after buying an additional 3,880 shares during the period. Finally, Americafirst Capital Management LLC purchased a new position in shares of Humana in the third quarter worth about $252,000. 94.19% of the stock is owned by hedge funds and other institutional investors.

WARNING: “Humana (HUM) Earns Buy Rating from Cowen” was originally published by Watch List News and is the property of of Watch List News. If you are viewing this report on another website, it was illegally copied and republished in violation of U.S. and international copyright law. The original version of this report can be accessed at https://www.watchlistnews.com/humana-hum-earns-buy-rating-from-cowen/1761709.html.

Humana Company Profile

Humana Inc is a health and well-being company. The Company’s segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.

Analyst Recommendations for Humana (NYSE:HUM)

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with Analyst Ratings Network's FREE daily email newsletter.